Skip to content
Stock screener

MRKR Marker Therapeutics, Inc. stock chart & analysis

Conviction 4HealthcareScan · Thu, Nov 19, 2026
Three inside up

Marker Therapeutics, Inc. (MRKR) closed at $1.32 (+54.71%) on Nov 19, 2026. Its latest daily candle is a three inside up. Price is above its 50-day and above its 200-day moving average. RSI(14) 68, RS Rating 86, -46.3% from its 52-week high, -11.4% year to date. Sector: Healthcare · Pharmaceutical Preparations.

MRKR$1.32+54.71%
ResistanceSupportVol 14
Loading chart…

Why MRKR moved

From the StockSetups movers recaps that covered MRKR, newest first. A recap states what was known that day.

Marker Therapeutics, Inc.Pharmaceutical Preparationswww.markertherapeutics.com ↗
Price1.32
Change+54.71%
Gap+18.38%
Rel volume482.05×
Avg volume3.04M
Avg $ vol3.97M
SMA 200.9495
SMA 501.04
SMA 2001.30
Price vs 50+27.53%
Price vs 200+1.16%
MA stackmixed
50/200 cross—
Supertrendup · 0.8299
RSI (14)68
MACD hist0.02
MACD crossbull · 0d
Stoch %K / %D59 / 29
ADX (14)20
+DI / −DI46 / 15
RSI divergence—
MACD divergence—
ATR %11.27%
ADR %12.94%
52w high2.46
52w low0.8101
From 52w high-46.34%
Above 52w low+62.94%
New 52w highNo
SqueezeFired
Bollinger width42.83%
%B1.41
Donchian pos59.30%
Donchian high1.67
Donchian low0.8101
AVWAP (52w high)1.39
vs AVWAP high-5.26%
AVWAP (52w low)1.32
vs AVWAP low-0.37%
OBV trendUp
Chaikin MF (20)-0.05
Today vs 20d482.05×
Avg vol (14d)4.3M
Avg vol (20d)3.04M
Avg $ vol (20d)3.97M
Market cap22.01M
RS Rating86 / 99
RS 3m (vs SPY)+1.48%
RS 6m (vs SPY)-4.07%
RS line new highNo
Trend template4/8
Technical rank77.7
1 week+46.67%
1 month+16.81%
3 months-5.04%
6 months-7.69%
1 year+30.69%
YTD-11.41%
P/E-1.81
P/B2.10
P/S6.21
P/FCF-1.78
EPS-0.7900
Div yield—
ROE-115.81%
ROA-97.31%
Debt/Eq0.01
Current6.26
EV/EBITDA—
Gross margin—
Net margin-342.96%
Rev growth-46.19%
EPS growth-13.35%
Price target—
Target upside—
Analyst rating—
Institutional23.81%
Ent. value13.04M
Revenue—
Net income-1.84M
Gross profit—
Free cash flow-12.39M
IndustryPharmaceutical Preparations
ExchangeNasdaq
Shares out16.67M
Employees5
ListedWed, Jan 7, 1998
Free float12.91M
Float %77.5%
Short interest—
Days to cover—
Short volume51.8%
Squeeze score—
Next earnings—
EPS forecast—
Last EPS vs est−$0.10 vs −$0.12
Last surprise+16.7% beat
Setup gradeD
Conviction4 / 100
Pattern quality—
Tech rank77.7 / 100
Group rank14 / 100
Status lane—
Setup direction—
Pattern family
Resistance—
Support—
Days since event—
Candle confirmThree inside up

Financials as of Wed, Sep 30, 2026 · quarterly.

MRKR technical analysis

Trend

MRKR's moving averages are mixed — no clean uptrend or downtrend. It closed 27.5% above the 50-day ($1.04) and 1.2% above the 200-day ($1.30). ADX(14) at 20 points to a moderate trend. It meets 4 of 8 trend-template criteria.

Momentum

RSI(14) is 68, in the bullish half of its range. MACD crossed above its signal line on the latest session. Its RS Rating of 86 puts its weighted 12-month performance ahead of about 86% of the US market.

Volume and volatility

Volume on the latest session ran 482.0× its 20-day average. It trades about $4.0M a day on average. ATR(14) is $0.1487, 11.3% of price — its typical daily range. A Bollinger Band squeeze just fired. On-balance volume is trending up.

Key levels

The 52-week range is $0.8101 to $2.46; price is 46.3% below the high and 62.9% above the low. The VWAP anchored at the 52-week high is $1.39, above price.

Performance

MRKR returned +46.7% (1 week), +16.8% (1 month), -5.0% (3 months), -7.7% (6 months), +30.7% (1 year), -11.4% (year to date).

About Marker Therapeutics, Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

Pharmaceutical Preparations · Listed 1998 · 5 employees

SEC filings

EDGAR filings in MRKR · 3 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.